Ryvu Therapeutics Email Formats
Biotechnology Research • 
Cracow, Lesser Poland Voivodeship, Poland • 201-500 Employees
Ryvu Therapeutics Email Formats
Ryvu Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@ryvu.com), used 50.9% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@ryvu.com | 50.9% |
{first initial}.{last name} | j.doe@ryvu.com | 47.9% |
Key Contacts at Ryvu Therapeutics
Chadi Saba
Early Clinical Development Medical Director
Jolanta Mazurek
Associate Director/Project Leader, Innovation & Discovery Support
Marcin Kowiel
Director, Data Science And Ai Platforms
Rostislav Kuklík
Medical Director
Aleksandra Sabiniarz
Research Operations Director
Maciej Rogacki
Associate Director / Dyrektor Jednostki Badawczej
Kamil Krzysztof Kus
Dmpk Director
Andrzej Mazan
Associate Director
Andrew Thomason
Director Drug Discovery
Anna Wilk
Director, Strategic Communications
Company overview
| Headquarters | ul. Leona Henryka Sternbacha 2, Kraków, Małopolska 30-394, PL |
| Phone number | +48122974690 |
| Website | |
| SIC | 283 |
| Keywords | AML, Oncology, Drug Discovery, Biotech, Immuno-Oncology, Cancer Metabolism, Synthetic Lethality, Hr-Mds, Kinase Inhibitor |
| Founded | 2007 |
| Employees | 201-500 |
| Socials |
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors, and SEL24 (MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia. In its history, Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, among others Merck, Menarini Group, Galapagos, Exelixis, and BioNTech. The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of sWIG80 index.
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Ryvu Therapeutics has 68 employees across 11 departments.
Departments
Number of employees
Funding Data
Explore Ryvu Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Ryvu Therapeutics Tech Stack
Discover the technologies and tools that power Ryvu Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Performance
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Programming languages
Chile
Korea, Republic of
United States
Canada
Frequently asked questions
4.8
40,000 users
